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A B S T R A C T  
The Medical Internal Radiation Dosimetry (MIRD) has developed methods, 
assumptions, models, and mathematical formulae for estimating internal 
radiation doses from the injected radiopharmaceuticals into the body. This 
study aims to determine the radiopharmaceutical distribution of Cobalt 57 
MIBI in four organs of patients identified as having breast cancer with the 
MIRD method with time variations. The four organs are the heart, thyroid, 
kidney, and liver. The absorption dose of each organ was calculated as the 
product of the cumulative activity and the S factor of each organ. The results 
showed that the highest uptake dose in these patients was in the thyroid and 
kidney organs, and then followed by the heart and liver. These results 
indicate that the thyroid and kidney organs are the most vulnerable organs 
due to injection of radiopharmaceutical into the body of breast cancer 
patients. 
1. Introduction  
Nuclear medicine has been used to diagnose many 
diseases and to treat many cases of cancers. In the 
nuclear medicine, radiopharmaceuticals are injected 
into the patient body. Injection of 
radiopharmaceuticals into the body allows those 
substances to be uniformly or non-uniformly 
distributed in organs and they will then emit 
radiation. The radiation released by the distributed 
radiopharmaceuticals in the organs is used for 
detecting abnormality inside the body or used to kill 
the cancers, depending on the type and dose of the 
radiation. The organ emitting the radiation is called 
as the source organs (s), and the organ absorbing the 
radiation is called the target organs (t). The fraction 
of radiation distributed and absorbed by the organs 
differs for each organ. In fact, the source organ can 
also be a target organ. It means that some organs 
perform well as both source and target. These 
include the heart, kidneys, thyroid, and liver. There 
are also organs that perform poorly as either source 
or target. An example of this is the breasts that do 
not effectively emit or absorb radiopharmaceutical 
doses. This means that radiopharmaceutical 
activities in the breasts are too small, and hence, they 
are neglected.   
An estimation of the dose absorbed by the organ 
is crucial for both diagnosis and therapy. However, 
the estimation of the absorbed by the organ is very 
complex. Many parameters influence to the dose 
distribution inside the body: physically, chemically, 
and biologically. Radiation estimation is essential for 
risk assessment, radiation protection, and treatment 
planning for treatment of cancer. The Medical 
Internal Radiation Dosimetry (MIRD) 
Committeeofthe Society of Nuclear Medicine (SNR) 
  
 
has developed methods, assumptions, models, and 
mathematical formulae for estimating internal 
radiation doses from the injected 
radiopharmaceuticals into the body [1]. The method 
is useful for estimating the radiation dose to the 
selected organs or all organs or the whole body from 
the injected radionuclides. 
One of the biggest causes of death in women is 
breast cancer, which can spread to women in the 
young and old age categories. The breast cancer cells 
can spread to other organs in the human body such 
as the lungs, bones, liver, etc. One of the ways to 
diagnose the spread of breast cancer cells in organs 
such as the lungs, liver, etc, is through injection of 
radiopharmaceutical with MIBI (Methoxyiso-
butylisonitrile) carrier substances [2]. 
The radiopharmaceutical injected into the 
patient's body has a high activity, around 15-20 mCi. 
Thus, monitoring of internal doses in the patient's 
body is needed to ensure the level of safety and 
fulfillment of the dose optimization [2]. Distribution 
of activities of the radiopharmaceutical in the 
bloodstream after being injected into the patient's 
body is measured using an open compartment 
system model [3]. radiopharmaceutical that is 
injected into the blood will then enter the heart. 
From the heart, this substance is transferred to the 
organs of thyroid and breasts. However, the 
substance that reaches the breasts is not effectively 
absorbed. It just passes the breasts and goes straight 
to both the kidney and liver. Combination of 
radiopharmaceutical emitted from the kidneys and 
liver will meet the radiopharmaceutical coming from 
the thyroid. Finally, all pharmaceutical will end at the 
excretion. 
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Previous studieson the calculation of the value of 
internal doses in various body organs were carried 
out. Suryanti[4] calculated the internal dose values 
in various bone-scan examination organsof Tc99m-
MDP MIBI by using the MIRD method. Hidayati et. al 
[5]calculated the dose distribution of 177Lu-DOTA 
TRASTUZUMAB radiopharmaceutical using the MIRD 
method. In this study, the S value was obtained using 
OLINDA / EXM software. Subsequent research was 
carried out by Hersela et. al. [6].The calculation of 
the internal dose value of 4 organs including the 
heart, thyroid, liver and kidney from injection of 
Tc99m MIBI with time variation was performed 
using the MIRD method. In the previous studies, the 
S value was obtained through MIRD table no. 11 [7]. 
This study aims to determine the 
radiopharmaceutical distribution of Cobalt 57 MIBI 
in 4 organs of patients identified as having breast 
cancer with MIRD method with time variations. The 
four organs of the patient's body are the heart, 
thyroid, kidney, and liver. 
  
2. Overview of The MIRD Method  
Calculation of the internal doses value of four organ 
components consisting of the heart, thyroid, kidney, 
and liver is done using the MIRD method. The value 
of total dose rate for the four organs (i = 1, 2, 3, 4) 
can be written as follows [3], 
 
    i ii s
i i
D D t A t
m

   
,                              (1) 
 
whereiis the radiation value of the i organ type 
emitted, iisvalues of specific absorption fraction,m 
is a mass of targetandtotal activity As(t) as a function 
of time defined as [1], 
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withA0 showing initial activity of the organ, while 
notations  and j are effective removal rates for 
both physical and biological cases respectively. They 
also relate to effective time of radiopharmaceutical 
activities as [1], 
 
 
ln 2
j eff
effT
    
.                   (3) 
 
The value of absorbed dose for MIRD of an organ can 
be calculated by integrating equation (1) from time t 
= 0 to time t= , which is [8], 
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Where A and S are accumulative activities, and the S, 
respectively.This S factor represent characteristics 
of radionuclide scattering, range of emitted radiation. 
The relationships of A values,S, and i can be 
written with the following formula [7,9],  
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Calculation for the value of S for all body organs can 
be obtained from MIRD table no. 11 [7], as is shown 
for the case of the heart, kidneys, thyroid, and liver. 
 
Table 1: Table for values of S for 4 source and target 
organs consisting of the heart, kidneys, thyroid, and liver 
from MIRD table no. 11 [7]. 
Target Organ (t) 
S (rad/Ci-jam) 
Source Organ (s) 
Heart 
(1) 
Kidne
ys (2) 
Thyro
id (3) 
Liver 
(4) 
Heart (1) 9.58 
E-05 
1.32 
E-06 
6.84 
E-08 
7.39 
E-07 
Kidneys   (2) 1.07 
E-06 
1.90 
E-04 
3.40 
E-08 
3.90 
E-06 
Thyroid   (3) 6.72 
E-07 
4.80 
E-08 
2.30 
E-03 
1.50 
E-07 
Liver     (4) 3.39 
E-06 
3.90 
E-06 
9.30 
E-08 
4.60 
E-05 
 
In Table 1, the S factor is defined by the relationship 
of target organ (t) and source organ (s) from 4 body 
organs of the heart, kidneys, thyroid, and liver (S 
value in Table 1 is a 4  4 matrix). For example, the 
target organ (t) for kidneys (2) and source organ (s) 
for thyroid (3) are in line 2 and column 3. Therefore, 
the value of S factor from the target kidneys to the 
source thyroid is written as, 
    83 2 3,40 10  rad/  Ci-jam.S s t S     
(6) 
 
From formulation (4), absorption dose for each 
organs of the heart, thyroid, kidneys, and liver is 
gained by multiplying the S factor (shown in Table 
1) with accumulative activities A . However, for the 
case of a set of body organs that relate to one 
another, formulation (4) for 4 different organs can 
be written as [7], 
 
4
1
i j
j
D A S i j

  
.                 (7) 
 
where i, j = 1, 2, 3, and 4, and each couple of 
 1 1,A D
,  
 2 2,A D ,  3 3,A D

and
 4 4,A D  are couples of 
accumulative activities and absorption dose for the 
heart (1), kidneys (2), thyroid (3),  and liver (4), 
while S(ij) is the value of S from target organ j to 
source organ i. The value of activity A in some of 
these organs can be calculated using equations 
A = count .CF,                               (8) 
WithCF is a correction factor that depends on the 
method and type of dose used in the research.  If the 
unit value of A is in mCi, then the unit value of CF is 
in mCi/count. The cumulative activity value can be 
written as  
   . . . ,A t A count CF  
 (9) 
With is the radiopharmaceutical residence time in 
the body. The value of accumulative activity per unit 
correction factor is defined as the multiplication of 
count and residence time, 
 
,
A t
T count
CF
  

          (10) 
In this paper, we use the calculation of the 
accumulative activity per unit correction factor of 
each organ studied, because we didn't calculate the 
correction factor of the organs. The accumulative 
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activity per unit correction factor can be calculated 
through a graph of the relationship between the 
count and time residence time from the MIRD 
method used. The relationship graph between count 
and residence time involving many organs of source 
and target at once. In this case, the value of 
accumulative activity per unit correction factor is 
the area below the relationship graph between count 
and residence time, as shown in Figure 1 as follows 
[10]: 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Example of calculation for T value from the area 
below the relationship graph between count and residence 
time involving many organs of source and target at once. 
 
Once an accumulative activity value from 4 
organs is calculated, absorption dose for each organ 
against radiopharmaceuticals injected into the blood 
can be known using formula (7). This formula can be 
elaborated into absorption dose per unit correction 
factor D for each organ of heart, kidneys, thyroid, 
and liver, based on equation (11a) - (11d) as follows, 
 
Heart :        1 1 2 3 41 1 1 2 1 3 1 4D T S T S T S T S        .  
(11a) 
Kidneys: . 
              (11b) 
Thyroid :        3 1 2 3 43 1 3 2 3 3 3 4D T S T S T S T S        .  
              (11c) 
Liver :        4 1 2 3 44 1 4 2 4 3 4 4D T S T S T S T S        .  
              (11d) 
 
3. Results and Discussion    
The research on accumulative activities was 
carried out on a patient who was identified as having 
breast cancer at Kariadi Hospital in Semarang 
Indonesia. This research uses oncology method and 
uses radiopharmaceuticals from Cobalt 57 MIDI with 
a dose of 20 mCi. Examination of MIRD at Kariadi 
Hospital aims to investigate the spread of breast 
cancer in organs around the breast organs by 
calculating the value of count and residence time on  
heart, thyroid, kidney and liverorgans. Residence 
time measurement is carried out in the hourly order 
for 5 measurements, namely at 0; 0.81; 1.14; 1.48; 
and 1.96 hours on 4 organs studied. 
In figure 2, the Count vs Time graph is described 
for four organs including heart, thyroid, kidney and 
liver. The accumulative activity per factor correction 
unit can be calculated of the Count vs Time graph as 
the sum of the area of the pentagonal which is 
bordered by the count axis, residence time axis and 
line equations. 
By using S factor value (table 1) and product 
values of count and time (hour) for 4 organs then we 
can be calculate absorption dose per unit correction 
factor D using the equation (11) where the indexes 
of each organs 1, 2, 3 and 4  show an indexes for 4 
organs. Table 2 shows the value of T as a product of 
the count and time and the value of absorption dose 
per unit correction factor D, for various organs 
including 4 organs. The D value is valid for the case 
from target organ t to source organ s (st)or vice 
versa(ts). 
 
 
 
Fig. 2: Graph of the relationship between count vs time 
(hour) of 4 organs, namely a. heart, b. thyroid, c. kidney 
and d. liver. The fourth graph above can be used to 
calculate the accumulative activity value of the 4 organs. 
 
From table 2, we get the calculation of the value 
of absorption dose per unit correction factor D for 
various organs with no significant difference 
between cases (st)or (ts), so it can be 
considered the D value is not far between the two 
the case (st) or (ts). The D and T values in table 
3 are valid if the correction factors for all organs are 
considered to be the same. The largest D value is 
obtained in the thyroid organ, and then followed by 
the kidney organ and finally the heart and liver 
organs. 
Table 2: The value of T (count×time) and 
comparison factors of absorption dose to correction 
factor values from the four organs that include heart, 
thyroid, kidney and liver 
 
No 
The 
Name 
of 
Organs 
T = 
count × 
time 
(hour) 
Absorption dose rad . count
correction factor Ci
D

 
  
 
 
1. Heart 200,095 20.6 (ts) 21.2  (st) 
2. Kidney 906,055 173 174 
3. Tyroid 185,375 427 426 
4. Liver 278,725 17.1 165 
 
It appears from equation (11) that the factor S, 
based on table 1, was similarly made for each patient. 
However, if we carefully look at the formulation of 
the S factor from equation (5), it will likely be 
different for different patients. Therefore, Hidayati 
[5] did not use the table no. 11 of the MIRD, but used 
OLINDA / EXM software to calculate the S value. 
From the results of the above study, the highest 
absorption dose in patients indicated as having 
breast cancer is in the thyroid and kidney and then 
followed by the heart and liver. This study may have 
a difference in absorption dose with other studies of 
[4] because the correction factor values for each 
organ are made the same as well as the difference in 
the value of the S factor used. 
When it is compared with the results of Hersela's 
study [6], the absorbed doses for the thyroid and the 
kidney are the highest value to reach the order of 
mGy, while the absorbed doses for the heart and the 
liver are in the order of 0.1 mGy, so the results of this 
       2 1 2 3 42 1 2 2 2 3 2 4D T S T S T S T S       
Count 
 
   /T A t CF   
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study are not significantly different from the results 
of the previous study. 
 
4. Conclusion 
 
This study was conducted on patients who were 
identified as having breast cancer and were given an 
oncological medical treatment using the MIRD 
method by giving a Cobalt 57 MIBI of 20 mCi dose. 
This oncology method is useful for diagnosing the 
spread of cancer cells to other body organs. However, 
it should be noted also about the level of absorption 
dose that may be received by the organs of the body 
so as not to endanger the body organs. The results 
showed that the highest uptake dose in these 
patients was in the thyroid and kidney organs, and 
then followed by the heart and liver. These results 
indicate that the thyroid and kidney organs are the 
most vulnerable organs affected by the continued 
negative effects of oncological therapy methods that 
inject radiopharmaceutical doses into the body of 
patients identified as a sufferer of breast cancer. 
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